CO2021006953A2 - Anticuerpos anti-claudina 18.2 y anti-4-1bb bispecificos y su uso - Google Patents

Anticuerpos anti-claudina 18.2 y anti-4-1bb bispecificos y su uso

Info

Publication number
CO2021006953A2
CO2021006953A2 CONC2021/0006953A CO2021006953A CO2021006953A2 CO 2021006953 A2 CO2021006953 A2 CO 2021006953A2 CO 2021006953 A CO2021006953 A CO 2021006953A CO 2021006953 A2 CO2021006953 A2 CO 2021006953A2
Authority
CO
Colombia
Prior art keywords
antibodies
claudin
bispecific
cells expressing
signaling
Prior art date
Application number
CONC2021/0006953A
Other languages
English (en)
Inventor
Lei Fang
Wenqing Jiang
Zhengyi Wang
Bingshi Guo
Eunsil Sung
Byungje Sung
Eunyoung Park
Original Assignee
I Mab Biopharma Us Ltd
Abl Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Us Ltd, Abl Bio Inc filed Critical I Mab Biopharma Us Ltd
Publication of CO2021006953A2 publication Critical patent/CO2021006953A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se proporcionan anticuerpos biespecíficos y multiespecíficos que se dirigen tanto a la claudina 18.2 (CLDN18.2) como a la 4-1BB. Estos anticuerpos, en ausencia de células que expresan CLDN18.2, pueden unirse a 4-1BB pero no pueden activar la señalización de 4-1BB. Sin embargo, en presencia de células que expresan CLDN18.2, estos anticuerpos pueden desencadenar la señalización 4-1BB dependiente de CLDN18.2, lo que conduce a una potente respuesta inmune a las células tumorales que expresan CLDN18.2.
CONC2021/0006953A 2019-08-12 2021-05-26 Anticuerpos anti-claudina 18.2 y anti-4-1bb bispecificos y su uso CO2021006953A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019100162 2019-08-12
CN2019104508 2019-09-05
CN2020071954 2020-01-14
CN2020087968 2020-04-30
PCT/CN2020/108707 WO2021027850A1 (en) 2019-08-12 2020-08-12 Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2021006953A2 true CO2021006953A2 (es) 2021-08-19

Family

ID=74570528

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0006953A CO2021006953A2 (es) 2019-08-12 2021-05-26 Anticuerpos anti-claudina 18.2 y anti-4-1bb bispecificos y su uso

Country Status (16)

Country Link
US (2) US11261259B2 (es)
EP (1) EP3853257A4 (es)
JP (2) JP7410141B2 (es)
KR (1) KR20210082482A (es)
CN (1) CN113166265A (es)
AU (1) AU2020329466A1 (es)
BR (1) BR112021008870A2 (es)
CA (1) CA3117740A1 (es)
CL (1) CL2021001375A1 (es)
CO (1) CO2021006953A2 (es)
IL (1) IL283379A (es)
MX (1) MX2021006428A (es)
PE (1) PE20211147A1 (es)
PH (1) PH12021551269A1 (es)
SG (1) SG11202104131VA (es)
WO (1) WO2021027850A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020320349A1 (en) * 2019-07-26 2022-02-17 Abl Bio Inc. Anti-EGFR/anti-4-1BB bispecific antibody and use thereof
AU2022330225A1 (en) * 2021-08-18 2024-02-29 Biotheus Inc. Bispecific antibody and use thereof
CN116410326A (zh) * 2021-12-30 2023-07-11 三优生物医药(上海)有限公司 抗cd40×cldn18.2双特异性抗体及其用途
WO2023134657A1 (zh) * 2022-01-11 2023-07-20 原启生物科技(上海)有限责任公司 抗cldn18.2和4-1bb的双特异性抗原结合蛋白及其用途
WO2023222135A1 (en) * 2022-05-20 2023-11-23 I-Mab Biopharma Co., Ltd. A method of treating solid tumor
WO2023232140A1 (en) * 2022-06-03 2023-12-07 Lanova Medicines Development Co., Ltd. Cancer treatment with a pd-1 or pd-l1 inhibitor and an antibody-drug conjugates targeting claudin 18.2

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
MX369276B (es) * 2012-11-13 2019-11-04 Biontech Ag Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015113576A1 (en) 2014-01-29 2015-08-06 Biontech Ag Peptide mimotopes of claudin 18.2 and uses thereof
US20210213138A1 (en) 2016-02-19 2021-07-15 Genisphere Llc Nucleic Acid Carriers And Therapeutic Methods of Use
US20200188528A1 (en) * 2016-12-19 2020-06-18 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
TWI829628B (zh) * 2016-12-19 2024-01-21 瑞士商赫孚孟拉羅股份公司 與靶向4-1bb (cd137)促效劑併用之組合療法
BR112019007267A2 (pt) * 2016-12-20 2019-07-09 Hoffmann La Roche anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
MA47200A (fr) 2017-01-03 2019-11-13 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CA3082321A1 (en) 2017-11-13 2019-05-16 Crescendo Biologics Limited Single domain antibodies that bind to cd137
US20220056136A1 (en) * 2018-11-30 2022-02-24 Abl Bio Inc. Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
WO2021101346A1 (en) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof

Also Published As

Publication number Publication date
JP7410141B2 (ja) 2024-01-09
PH12021551269A1 (en) 2021-11-03
PE20211147A1 (es) 2021-06-28
EP3853257A1 (en) 2021-07-28
WO2021027850A1 (en) 2021-02-18
US20210317224A1 (en) 2021-10-14
KR20210082482A (ko) 2021-07-05
EP3853257A4 (en) 2022-06-29
JP2022543508A (ja) 2022-10-13
CN113166265A (zh) 2021-07-23
AU2020329466A1 (en) 2021-05-27
US11261259B2 (en) 2022-03-01
SG11202104131VA (en) 2021-05-28
JP2023182853A (ja) 2023-12-26
MX2021006428A (es) 2021-11-17
BR112021008870A2 (pt) 2021-11-30
IL283379A (en) 2021-07-29
US20220348675A1 (en) 2022-11-03
CL2021001375A1 (es) 2022-01-07
CA3117740A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
CO2021006953A2 (es) Anticuerpos anti-claudina 18.2 y anti-4-1bb bispecificos y su uso
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CO2018000992A2 (es) Anticuerpos anti-pd-1 novedosos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
PH12020500667A1 (en) Multispecific antibodies and use thereof
MX2017000187A (es) Proteinas de union a cd33 y cd3 biespecificas.
CR20170109A (es) Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos
MX2017015380A (es) Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
MX2020004561A (es) Anticuerpos biespecificos que se unen a alk-1 y bmpr-2.
PE20201419A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
PE20210110A1 (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso
AR115963A1 (es) Anticuerpos anti-il1rap y métodos de uso de estos
BR112021012631A2 (pt) Anticorpos anti-ctla4 e métodos de uso dos mesmos
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
CO2021011906A2 (es) Anticuerpos claudina 6 y usos de los mismos
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
CO2023015593A2 (es) Terapias basadas en il2 y métodos de uso de las mismas
MX2020003672A (es) Proteinas de fusion inmunomoduladora.